Mental Disorders Commons^™

Neuroinflammation And Its Role In Depression– A Review Of Emerging Biomarkers And Therapeutic Targets, Sophia M. Valerino

Advances in Clinical Medical Research and Healthcare Delivery

Major depressive disorder (MDD) is a prevalent and debilitating mental illness that affects millions globally. Traditionally, the pathophysiology of MDD was thought to be due primarily neurotransmitter imbalances. However, emerging research highlights the role of neuroinflammation in MDD pathogenesis. Elevated levels of pro-inflammatory cytokines, microglial activation, and blood-brain barrier dysfunction have been implicated in the etiology of MDD. Additionally, biomarkers such as C-reactive protein and neuroimaging findings further support the neuroinflammatory hypothesis. This growing body of evidence has led to increased interest in novel treatment approaches, including anti-inflammatory medications and lifestyle interventions, as potential therapeutic strategies. While selective serotonin reuptake …

Qi Project On Depression Screening Phq2 And Phq9 In Kingwood Im Clinic, Anam Zara, Sara Shahid, Anusha Putta

Gulf Coast Division GME Research Day 2025

No abstract provided.

Case Report Of Tricyclic Antidepressant Toxicity With Prolonged Qt/Qtc And Widened Qrs On Ekg, Alexandra Doan, Joshua Wilkes, Jonathan Leggett, Jarratt Lark

South Atlantic Division GME Research Day 2025

No abstract provided.

Fda Approval Of Zuranolone: A Breakthrough Treatment For Postpartum Depression, Connor Dains, Makayla Eversole, Kiley Devoll, Daniella Egbujor, Marisa Petrunich, Madilyn Paphanchith, Joshua Honaker, Samantha Mccord, Manoranjan D'Souza

Pharmacy and Wellness Review

Postpartum depression (PPD) is a serious medical condition that increases the risk of postpartum mortality and affects the ability of a postpartum individual to take care of their newborn. Until 2023, intravenously-administered brexanolone was the only Food and Drug Administration (FDA)-approved medication for PPD. Brexanolone’s route of administration poses significant barriers to accessibility and convenience. Other treatment options, such as psychotherapy and antidepressants, often require long-term commitment and may not provide rapid relief for severe symptoms. In August 2023, the FDA approved zuranolone as an oral medication for PPD, which enhances treatment accessibility and offers patients a more flexible, outpatient …

Cognitive Behavioral Therapy (Cbt) Interventions For Group Therapy For College Students Experiencing Depression, Ty Ogren

Dissertations, Theses, and Projects

This group manual was created to support college students struggling with a depressive mood disorder such as Major Depressive Disorder. The instance of mental health concerns, including depression, have increased greatly over the last several years. Depression is the most common mental health concern for college students, and the rate at which they experience depressive symptoms has exceeded that of the general population. Depressive symptoms in college students can lead to many concerns like poor academic achievement, self-isolation, poor diet and nutrition, and suicidal ideation (Liu et al., 2022). This group manual aims to equip college students struggling with depression …

High-Dose Psilocybin Reduces Depressive Symptoms In Patients With Major Depressive Disorder, Brandon Lien, Jason A. Mckechnie

Physician Assistant Capstones, 2020-current

No abstract provided.

A Brief Review Of Zuranolone, Aubrey A. Jackson

Transformative Medicine

Zuranolone, a novel analog of allopregnanolone, has been approved by the U.S. Food and Drug Administration (FDA) as the first oral medication approved for the treatment of postpartum depression in adults. Developed by Sage Therapeutics under the brand name Zurzuvae, zuranolone was approved by the FDA on August 4^th, 2023.¹ Zuranolone is a modified version of brexanolone (sold under the brand name Zulpresso), an intravenously administered allopregnanolone formulation that was previously the only FDA-approved medication for postpartum depression. Zuranolone offers a more accessible treatment option for patients with efficacy established in clinical trials. Its approval expands the …

Individual Differences In Cannabis Use Disorder With Implications For Endocannabinoid Modulation In Therapeutics Development, Erin L. Martin

MUSC Theses and Dissertations

Cannabis use disorder (CUD) is increasingly prevalent in the United States, but there is no effective pharmacological means to treat it. The endocannabinoid (eCB) system has emerged as a candidate therapeutic target demonstrating some evidence of efficacy in treating CUD. However, clinical trials evaluating eCB-modulating therapeutics have historically undervalued individual differences that could contribute to variation in treatment outcome (e.g. sex, comorbid psychiatric illness). To address this gap in the literature, the present set of studies (a) compared plasma eCB tone in groups underrepresented in treatment trials for CUD (females, individuals with comorbid major depressive disorder; MDD/CUD) with males or …

Improving Depression Screening In Primary Care By Implementing A Systematic Annual Screening Protocol: A Quality Improvement Initiative, Trang Nguyen, Ian Whitaker, Danny Tran, Aidan Lum Kong, Nan Crossley

South Atlantic Division GME Research Day 2024

No abstract provided.

Improving Competence And Confidence In Outpatient Management Of Major Depressive Disorder, Anish Pal, Pavan Anand, Brett M. Garrett

Gulf Coast Division GME Research Symposium 2024

No abstract provided.

The Etiology Of Mdd In Sexual Minority Youth And Its Implications For Treatment, Keith Burns

Intuition: The BYU Undergraduate Journal of Psychology

Greater tolerance and understanding of homosexuality, transgenderism, and other forms of gender nonconformity have sparked an increased effort to reach out to and help sexual minorities (i.e., groups whose sexual identity, orientation, or practices differ from cisgender heterosexuality), especially those who experience mental health challenges. Despite immense progress in society, deeply rooted social stigma, prejudice, and discrimination have often left sexual minorities feeling bullied, ostracized, and isolated, which tends to reinforce a host of negative mental health outcomes, such as increased risk of major depressive disorder (MDD) and suicidality (Hatchel et al., 2018). While mental health clinicians have become increasingly …

Time For Some Drugs Or Drugs For Some Time, Linda Zhang, Lauren Wilson, Benjamin Pierce

Psychiatry

No abstract provided.

Therapeutic Potential Of A Ketogenic Diet In The Treatment Of Major Depressive Disorder, Jordan A. Murrin

Masters Theses, 2020-current

Major depressive disorder (MDD) is the second most common mental health condition and a leading cause of disability in the world. It is theorized that MDD develops from a combination of biological, psychological, and social stressors. The condition is typically treated using pharmaceuticals and psychotherapy. However, not all individuals with MDD have access to or choose to use these treatments, or may prefer to incorporate therapeutic lifestyle changes such as exercise, sleep, and healthy eating. Even with treatment, MDD can alter brain structure and function, leading to the development of comorbid mental health and chronic metabolic conditions like obesity, cardiovascular …

Predictors And Health Outcomes Of Treatment-Resistant Depression Among Adults With Chronic Non-Cancer Pain Conditions And Major Depressive Disorder, Drishti Shah

Graduate Theses, Dissertations, and Problem Reports (ETD)

Understanding major depressive disorder (MDD) as a comorbidity in patients with chronic non-cancer pain conditions (CNPC) is of importance because of the high prevalence and well documented bi-directional relationship between MDD and pain. Furthermore, presence of CNPC among adults with MDD often reduces benefits of antidepressant therapy, thereby increasing the possibility of treatment resistance. Treatment-resistant depression (TRD) commonly defined as insufficient response to multiple antidepressant trials, often worsens depression and pain symptoms and can amplify the clinical and economic burden among adults with CNPC and MDD. Additionally, long-term opioid therapy (LTOT) may be prescribed at a higher rate to adults …

Is Incidence Of Nausea Influenced By Brintellix In Patients Over The Age Of 18 With Major Depressive Disorder?, Juris Eyler

PCOM Physician Assistant Studies Student Scholarship

OBJECTIVE: The Objective of this selective EBM review is to determine where or not, “Is Incidence of Nausea Influenced by Brintellix (Vortioxetine) in Patients over the Age of 18 with Major Depressive Disorder (MDD)?”

STUDY DESIGN: Review of three English language primary studies, published between 2011 and 2013

DATA SOUCES: Three double blind randomized controlled trials (RCTs). Sources were found on PubMed and Cochrane Library databases.

OUTCOMES MEASURED: To measure the incidence of nausea in patients over 18 who are diagnosed with major depressive disorder taking Brintellix compared to a placebo.

RESULTS: The randomized controlled studies results found that Brintellix …